Abstract
Escape variants can cause new waves of COVID-19 outbreaks and put vaccination strategies at risk. To prevent or delay the global spread of these waves, virus mobility needs to be minimised through screening and testing strategies, which should also cover vaccinated people. The costs of these strategies are minimal compared to the costs to health, society and the economy from another wave.
Footnotes
Martin Hellwig, Max Planck Institute for Research on Collective Goods, Bonn, Germany.
Viola Priesemann, Max Planck Institute for Dynamics and Self-Organization, Göttingen, Germany.
Guntram B. Wolff, Bruegel, Brussels, Belgium.
Contributor Information
Martin Hellwig, Email: hellwig@coll.mpg.de.
Viola Priesemann, Email: viola.priesemann@ds.mpg.de.
Guntram B. Wolff, Email: guntram.wolff@bruegel.org
References
- Andreano, E., G. Piccini, D. Licastro, L. Casalino, N. V. Johnson, I. Paciello, S. Dal Monego, E. Pantano, N. Manganaro, A. Manenti, R. Manna, E. Casa, I. Hyseni, L. Benincasa, E. Montomoli, R. E. Amaro, J. S. McLellan and R. Rappuoli (2020), SARSCoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma, bioRxiv, 2020.12.28.424451.
- Castillo J C, Ahuja A, Athey S, Baker A, Budish E, Chipty T, Glennerster R, Kominers S D, Kremer M, Larson G, Lee J, Prendergast C, Snyder C M, Tabarrok A, Tan B J, Wiecek W. Market design to accelerate COVID-19 vaccine supply. Science. 2021;371(6534):1107–1109. doi: 10.1126/science.abg0889. [DOI] [PubMed] [Google Scholar]
- Contreras S, Dehning J, Loidolt M, Zierenberg J, Spitzner F P, Urrea-Quintero J H, Mohr S B, Wilczek M, Wibral M, Priesemann V. The challenges of containing SARS-CoV-2 via test-trace-and-isolate. Nature Communications. 2021;12:378. doi: 10.1038/s41467-020-20699-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Cutler D M, Summers L H. The COVID-19 Pandemic and the $16 Trillion Virus. JAMA. 2020;324(15):1495–1496. doi: 10.1001/jama.2020.19759. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Cyranoski D. Alarming COVID variants show vital role of genomic surveillance. Nature. 2021;589:337–338. doi: 10.1038/d41586-021-00065-4. [DOI] [PubMed] [Google Scholar]
- Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz M A, Hernán M A, Lipsitch M, Reis B, Balicer R D. BNT162b2 mR-NA, Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. New England Journal of Medicine. 2021;384:1412–1423. doi: 10.1056/NEJMoa2101765. [DOI] [PMC free article] [PubMed] [Google Scholar]
- McCormick K D, Jacobs J L, Mellors J W. The emerging plasticity of SARS-CoV-2. Science. 2021;371(6536):1306–1308. doi: 10.1126/science.abg4493. [DOI] [PubMed] [Google Scholar]
- Oliu-Barton M, Pradelski B, Aghion P, Artus P, Kickbusch I, Lazarus J V, Sridhar D, Vanderslott S. SARS-CoV-2 elimination, not mitigation, creates best outcomes for health, the economy, and civil liberties. Lancet. 2021;397(10291):2234–2236. doi: 10.1016/S0140-6736(21)00978-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Phillips N. The coronavirus is here to stay — here’s what that means. Nature. 2021;590:382–384. doi: 10.1038/d41586-021-00396-2. [DOI] [PubMed] [Google Scholar]
- Priesemann V, Brinkmann M M, Ciesek S, Cuschieri S, Czypionka T, Giordano G, Gurdasani D, Hanson C, Hens N, Iftekhar E, Kelly-Irving M, Klimek P, Kretzschmar M, Peichl A, Perc M, Sannino F, Schernhammer E, Schmidt A, Staines A, Szczurek E. Calling for pan-European commitment for rapid and sustained reduction in SARS-CoV-2 infections. Lancet. 2021;397(10269):92–93. doi: 10.1016/S0140-6736(20)32625-8. [DOI] [PMC free article] [PubMed] [Google Scholar]